Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.
You may also be interested in...
Quintiles-Invested Samsung Biologics Proceeds On Schedule
SEOUL - South Korea's largest conglomerate Samsung Group announced April 22 the CEO and the company name of a joint venture with Quintiles Transnational Corp. making inroads into the biosimilar and biopharmaceutical business
Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials
Asia Pacific Key To Speeding Up Global Drug Development, Says Quintiles VP Anand Tharmaratnam (Part 1 Of 2)
Globalization of clinical trials is perhaps Asia's main role in advancing the pharmaceutical industry, says Quintiles Asia Pacific Head of Clinical Development Anand Tharmaratnam, who discussed innovation in Asia Pacific with PharmAsia News' Australia Bureau. Key to that innovation is a lack of legacy informationin that the past is not holding the industry back, and virtual opportunitiesand private/public cooperative partnerships offer ripe benefits.